Spring Research Update Meeting 2025
Our 2025 Spring Research Update Meeting will take place at BMA House, home of the British Medical Association, in Tavistock Square, London on 24 March where we invite guests to an inspiring agenda of some of the most up to date news of our funded...
Learn more
Webinar – Coronavirus and Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. This webinar discusses recent publications about Coronavirus and Parkinson’s. The eminent panel, once again chaired by Professor Patrik Brundin (Van Andel Institute) comprises Dr Alberto Fasano (University of Toronto), Dr David Beckham…
The need for novel c-Abl inhibitors
A protein called Abelson Tyrosine Kinase – or c-Abl – is believed to be involved in the biological processes leading to loss of dopamine neurons in the brains of people with Parkinson’s. In many preclinical studies, stopping the harmful c-Abl processes with the use of drugs called c-Abl inhibitors have found that c-Abl activity decreases….
The AIM-PD trial (ambroxol)
Supported and funded by Cure Parkinson’s, Van Andel Institute and the John Black Foundation, the next phase of this trial programme will follow shortly. Phase 2 of the ‘AIM-PD’ study was a proof of concept study and involved 17 people with the genetic form of Parkinson’s over…
The UP-Study trial (UDCA)
This trial is now complete. Supported by Cure Parkinson’s and the J P Moulton Foundation, the results are expected in 2021. Originally used to treat cirrhosis of the liver, researchers found that the rescue effect of UDCA on the liver cells may actually be due…
TGF-beta: The Parkinson’s superfamily?
A lot of Parkinson’s research has focused on a neurotrophic factor called glial cell-derived neurotrophic factor (or GDNF). But GDNF only represents a small fraction of a much larger class of neurotrophic factors, called the Transforming growth factor-β (TGF-β) superfamily. Recently, researchers have been investigating some of the other TGF-β family […]